179 related articles for article (PubMed ID: 24633048)
1. SOCS3 promoter hypermethylation is a favorable prognosticator and a novel indicator for G-CIMP-positive GBM patients.
Feng Y; Wang Z; Bao Z; Yan W; You G; Wang Y; Hu H; Zhang W; Zhang Q; Jiang T
PLoS One; 2014; 9(3):e91829. PubMed ID: 24633048
[TBL] [Abstract][Full Text] [Related]
2. LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients.
Mock A; Geisenberger C; Orlik C; Warta R; Schwager C; Jungk C; Dutruel C; Geiselhart L; Weichenhan D; Zucknick M; Nied AK; Friauf S; Exner J; Capper D; Hartmann C; Lahrmann B; Grabe N; Debus J; von Deimling A; Popanda O; Plass C; Unterberg A; Abdollahi A; Schmezer P; Herold-Mende C
Int J Cancer; 2016 Jul; 139(2):424-32. PubMed ID: 26934681
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide DNA methylation profiling identifies ALDH1A3 promoter methylation as a prognostic predictor in G-CIMP- primary glioblastoma.
Zhang W; Yan W; You G; Bao Z; Wang Y; Liu Y; You Y; Jiang T
Cancer Lett; 2013 Jan; 328(1):120-5. PubMed ID: 22960273
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation profiles of long- and short-term glioblastoma survivors.
Shinawi T; Hill VK; Krex D; Schackert G; Gentle D; Morris MR; Wei W; Cruickshank G; Maher ER; Latif F
Epigenetics; 2013 Feb; 8(2):149-56. PubMed ID: 23291739
[TBL] [Abstract][Full Text] [Related]
5. Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme.
Martini M; Pallini R; Luongo G; Cenci T; Lucantoni C; Larocca LM
Int J Cancer; 2008 Dec; 123(12):2955-60. PubMed ID: 18770864
[TBL] [Abstract][Full Text] [Related]
6. Reciprocal regulation of SOCS 1 and SOCS3 enhances resistance to ionizing radiation in glioblastoma multiforme.
Zhou H; Miki R; Eeva M; Fike FM; Seligson D; Yang L; Yoshimura A; Teitell MA; Jamieson CA; Cacalano NA
Clin Cancer Res; 2007 Apr; 13(8):2344-53. PubMed ID: 17438093
[TBL] [Abstract][Full Text] [Related]
7. SOCS3 Methylation Predicts a Poor Prognosis in HBV Infection-Related Hepatocellular Carcinoma.
Zhang X; You Q; Zhang X; Chen X
Int J Mol Sci; 2015 Sep; 16(9):22662-75. PubMed ID: 26393582
[TBL] [Abstract][Full Text] [Related]
8. Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients.
Mur P; Rodríguez de Lope Á; Díaz-Crespo FJ; Hernández-Iglesias T; Ribalta T; Fiaño C; García JF; Rey JA; Mollejo M; Meléndez B
J Neurooncol; 2015 May; 122(3):441-50. PubMed ID: 25682093
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation.
Jha P; Pia Patric IR; Shukla S; Pathak P; Pal J; Sharma V; Thinagararanjan S; Santosh V; Suri V; Sharma MC; Arivazhagan A; Suri A; Gupta D; Somasundaram K; Sarkar C
Neuro Oncol; 2014 Dec; 16(12):1607-17. PubMed ID: 24997139
[TBL] [Abstract][Full Text] [Related]
10. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.
van den Bent MJ; Gravendeel LA; Gorlia T; Kros JM; Lapre L; Wesseling P; Teepen JL; Idbaih A; Sanson M; Smitt PA; French PJ
Clin Cancer Res; 2011 Nov; 17(22):7148-55. PubMed ID: 21914791
[TBL] [Abstract][Full Text] [Related]
11. Hypermethylation of the proapoptotic gene TMS1/ASC: prognostic importance in glioblastoma multiforme.
Martinez R; Schackert G; Esteller M
J Neurooncol; 2007 Apr; 82(2):133-9. PubMed ID: 17048097
[TBL] [Abstract][Full Text] [Related]
12. The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma.
Ohka F; Natsume A; Motomura K; Kishida Y; Kondo Y; Abe T; Nakasu Y; Namba H; Wakai K; Fukui T; Momota H; Iwami K; Kinjo S; Ito M; Fujii M; Wakabayashi T
PLoS One; 2011; 6(8):e23332. PubMed ID: 21829728
[TBL] [Abstract][Full Text] [Related]
13. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y
J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344
[TBL] [Abstract][Full Text] [Related]
14. CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme.
Martinez R; Setien F; Voelter C; Casado S; Quesada MP; Schackert G; Esteller M
Carcinogenesis; 2007 Jun; 28(6):1264-8. PubMed ID: 17272309
[TBL] [Abstract][Full Text] [Related]
15. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.
Noushmehr H; Weisenberger DJ; Diefes K; Phillips HS; Pujara K; Berman BP; Pan F; Pelloski CE; Sulman EP; Bhat KP; Verhaak RG; Hoadley KA; Hayes DN; Perou CM; Schmidt HK; Ding L; Wilson RK; Van Den Berg D; Shen H; Bengtsson H; Neuvial P; Cope LM; Buckley J; Herman JG; Baylin SB; Laird PW; Aldape K;
Cancer Cell; 2010 May; 17(5):510-22. PubMed ID: 20399149
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma.
An C; Choi IS; Yao JC; Worah S; Xie K; Mansfield PF; Ajani JA; Rashid A; Hamilton SR; Wu TT
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):656-63. PubMed ID: 15701853
[TBL] [Abstract][Full Text] [Related]
17. Methylation-associated dysregulation of the suppressor of cytokine signaling-3 gene in multiple myeloma.
Wilop S; van Gemmeren TB; Lentjes MH; van Engeland M; Herman JG; Brümmendorf TH; Jost E; Galm O
Epigenetics; 2011 Aug; 6(8):1047-52. PubMed ID: 21934357
[TBL] [Abstract][Full Text] [Related]
18. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X
Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577
[TBL] [Abstract][Full Text] [Related]
19. SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation.
Liu F; Cox CD; Chowdhury R; Dovek L; Nguyen H; Li T; Li S; Ozer B; Chou A; Nguyen N; Wei B; Antonios J; Soto H; Kornblum H; Liau L; Prins R; Nghiemphu PL; Yong W; Cloughesy T; Lai A
J Neurooncol; 2019 May; 142(3):423-434. PubMed ID: 30838489
[TBL] [Abstract][Full Text] [Related]
20. CXCR4 expression varies significantly among different subtypes of glioblastoma multiforme (GBM) and its low expression or hypermethylation might predict favorable overall survival.
Ma X; Shang F; Zhu W; Lin Q
Expert Rev Neurother; 2017 Sep; 17(9):941-946. PubMed ID: 28685624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]